BIOCAD Risk Report

📜 Innovation & R&D

BIOCAD, a company known for its contributions to the pharmaceutical industry, has made significant strides in innovation and research and development. Their commitment to developing both biosimilars and original drugs has positioned them as key players in the industry, particularly in the Russian market.

• BIOCAD announced the deadline for registration of the first hemophilia drug in the Russian Federation on 🗓 2025-07-14.
• On 🗓 2025-04-17, BIOCAD filed registration documents for Russia’s first hemophilia drug.
• The company launched Russia's first drug for the treatment of ankylosing spondylitis on 🗓 2024-05-07.
• BIOCAD started the development of an original drug for the treatment of multiple myeloma on 🗓 2023-03-11.
• In 2023, on 🗓 2023-07-10, BIOCAD initiated clinical trials for a drug targeting hemophilia.

⚖️ Legal & Regulatory

BIOCAD has been involved in legal and regulatory activities crucial to their operations in various markets. Ensuring compliance and addressing legal challenges remains a focus as they expand their presence globally.

• Roche faced BIOCAD in patent litigation, likely to shape Russia’s IP landscape on 🗓 2016-03-09.